Adoptive Cell Transfer Congress

When

2019年10月10-11日
Registration from 8am

Where

英國,倫敦
London Heathrow Marriott Hotel

Adoptive Cell Transfer Congress
-過繼細胞轉移學會-
日期:2019年10月10-11日
地點:英國,倫敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Adoptive Cell Transfer Congress

針對使用CAR與TCR等新穎的先進治療法進行分析

製藥公司及大學學者針對CAR-T (嵌合抗原受體T細胞) 細胞療法的最新研究成果以及T細胞受體(TCR)療法的潛力領域進行發表。演講內容主要針對以下主題的設計與研發戰略,包括:患者及捐贈者的T細胞重組、受體的改變、標的的選定等。討論臨床運用的進展以及尚未解決的課題。

“I liked the fact that the conference was really focused ... allowing to learn and discuss specific subjects with experts in the field”

“Excellent opportunity to discuss topics in detail and to network”.

“The research sessions were very good and of high quality”

本學會是以癌症免疫療法相關研究與技術為主題的系列活動之一。報名參加本會議的與會者,可免費前往以下五個會議並聆聽超過100個以上的演講,另外能夠在專業領域擴展人脈,吸收新知。

您可參加同時舉辦的這系列所有學會

 

2019年10月10日(四) – 細胞工程


專題演講: 針對頭部及頸部的癌症採取T4 ErbB標的化CAR-T細胞免疫療法:第一臨床試驗的結果
JOHN MAHER, Senior Research Fellow, King’s College London
• A CAR has been engineered using a promiscuous ligand that engages 8 distinct ErbB dimer species
• Phase 1 evaluation has been initiated in patients with head and neck cancer, using intra-tumoural delivery and phased dose escalation to mitigate risk
• Fourteen patients have been safely treated to date, at doses of up to 1Bn cells, without DLTs and with an efficacy signal evident.
專題演講: 對應CAR-T細胞重組的TALEN平台
LAURENT POIROT, VP Immunology Department, Cellectis
• TALEN-mediated gene editing is highly efficacious, precise and specific
• Incorporation of gene-editing in a robust manufacturing process is leveraged to maximize the potential benefits of allogeneic approach in haematological malignancies
• The complexity of genome editing can now be increased to tackle even more difficult cancers.


Morning Refreshments / Poster Presentations


Developing TIL based treatment for solid tumours
ROBERT HAWKINS, CEO Immetacyte Ltd /Honorary Professor Medical Oncology, University of Manchester
• Background to TIL therapy and potential benefits in solid tumours
• Clinical results in melanoma
• Pre-clinical data in other tumours
• Engineering TIL to produce second generation products
Beyond CD19: multi-targeted adoptive cell therapy for solid tumors
STEFFEN WALTER, CSO, Immatics US
CAR-T therapies are revolutionizing the treatment of haematologic malignanices but have shown limited success in solid tumors. TCR-T based approaches have delivered historically better response rates in solid tumors, but are critically lacking validated targets for large cancer indications. XPRESIDENT® is the leading platform for the discovery of novel targets for all types of TCR-T therapy. XCEPTOR® is a leading platform for the discovery of affinity-tuned, safer T-cell receptors. Together, these technologies have enabled a pipeline of clinical-stage adoptive cell therapy programs, namely ACTolog® and ACTengine®, which include one of the first clinical trials to apply multi-targeted TCR-T to solid tumor patients


Lunch


NK Cell Stimulation Using Membrane Bound IL-21
ROBERT IGARASHI, CSO, Cytosen Therapeutics
• Addressing the needed for an effective and robust methodology for efficient production of large doses of NK cells with high anti-tumor potency
• NK cell stimulation for production of high dosages and repeat dosages of highly potent NK cells.
• Advancing clinical development of NK cell therapeutics for treatment of AML in the near future
The potential of natural killer cells as novel therapeutics
BOB VALAMEHR (Reserved), Vice President of Cancer Immunotherapy, Fate Therapeutics
Engineering NK cell formats
Rivogenlecleucel (Rivo-cel™): Making a Difference in Pediatric Leukemias & Orphan Blood Disorders
KAI CHAN, VP EU Head of Medical Affairs, Bellicum Pharmaceuticals


Networking Drinks Reception


2019年10月11日(五) - 個案研究與戰略

專題演講: T細胞受體基因改變輸入療法:針對未來的技術革新
DOLORES SCHENDEL, CEO and CSO, Medigene
• First generation TCR-Ts are in numerous clinical studies
• Innovations will alter new generation TCR-Ts going forward
• Innovations have potential to change safety and efficacy of cellular products
• Innovations can improve manufacturing and reduce cost of goods
Understanding drivers of clinical pharmacology for engineered T cell products
CEDRIK BRITTEN, Head of Oncology Cell Therapy Research Unit (OCT RU), GSK
• Selection of antigen(s) for CAR/TCR T cells
• Design of immune-receptor constructs
• Efficacy-enhancement technologies to drive benefit in patients with solid cancer
• Selection of dose for CAR/TCR-T
• Update on clinical development of GSK3377794 (NY-ESO TCR-T)


Morning Refreshments / Poster Presentations


Starting up clinical trials with TCR-modified T cells in solid cancers
MONA WELSCHOF, Director Clinical Development, Zelluna Therapeutics
• Introduction of Zelluna’s TCR-modified T cell Approach
• Pinpointing the importance of understanding the regulatory pathways and early interactions with regulatory authorities
• Discussion of the various operational challenges in setting up adoptive cell therapy trials
Exploring the regulatory landscape for cell therapies
VICKI COUTINHO (Reserved), Senior Director Regulatory Affairs, Autolus


Lunch


Combining Innate and Adaptive Immunity: Using NK Receptors for CAR T Cell Therapy
PEGGY SOTIROPOULOU, Director, Research & Development, Celyad
• Leveraging NKG2D receptor for cancer immunotherapy
• Autologous NKG2D-based CAR T cells to target hematopoietic and solid tumours
• Non-gene edited allogeneic NKG2D-based CAR T cell therapy
GUCY2C CAR-T cell Therapy for Metastatic Colorectal Cancer
ADAM SNOOK, Assistant Professor of Pharmacology and Experimental Therapeutics, Thomas Jefferson University
Guanylyl cyclase C (GUCY2C) is a cell surface receptor expressed in the apical brush border membrane of intestinal epithelial cells and an emerging target for cancer immunotherapy. GUCY2C is expressed throughout the intestinal tumorigenesis processes from benign adenomas to metastatic adenocarcinomas in nearly all colorectal cancers, making it an attractive target for cancer immunotherapy. Here, I describe our approach to develop an adoptive cell therapy (ACT) paradigm employing T cells engineered to express a chimeric antigen receptor (CAR) targeting GUCY2C. In preclinical studies, GUCY2C CAR-T cells eliminated bulky colorectal cancer metastases, without toxicity, positioning this therapy for translation to clinical studies in patients with colorectal cancer, the 3rd leading cause of cancer-related death in the world.
Advancing CAR T products for targeting solid tumors to the clinic
CHRIS KLOSS (Reserved), Scientist, Janssen


Chair’s Closing Remarks / Conference Close


* 活動內容有可能不事先告知作更動及調整。

 

議程

此學會預計有超過350位專家齊聚一堂,致力研究治療癌症的強力武器——患者及捐贈者的T細胞重組技術為主要對象。

Download the Agenda (PDF)

演講者

贊助商

所有贊助商名單

地點

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海報發表

海報發表不僅在休息時間進行,也會與分科會討論同時進行。所有藥廠或研究機構的研究人員所製作的海報,都必須在獲得學會事務局許可後張貼於會場內指定區域。

此外,學會閉幕後,將發給所有出席者匯集海報發表大綱的電子書,亦可將海報以.pdf形式的檔案公開(僅限意者)。

海報發表對於尋求出資和雇用機會的人,以及希望在志同道合、研究同一題目的研究者團體中發表成果的人來說,是能夠在會場內廣受矚目的珍貴機會。

必須報名參加本年會方可進行海報發表。張貼海報的空間有限,將依報名順序接受通過審查者張貼海報,故建議盡早申請。

企業發表海報需要支付100英鎊管理費用。費用包括區域保留費用與展示板費用以及各種其他手續費。研究機構與非營利組織可免費發表。

海報發表報名辦法

請填寫專用表格(點擊下列連結下載)於2019年9月20日以前繳交。若於截止日期前額滿將提早截止報名,敬請儘早申請。詳情歡迎與我們聯繫。

會議贊助商

贊助商募集

藉由成為本年會的贊助商或參展者,可在融洽的氣氛中,與各組織的代表於各種正式、非正式的場合進行會談,建立合作關係的機會。

本年會準備了各種贊助方案,豐富的選項可配合您的業務需求自由搭配,以獲取最大額度的投資報酬。

欲採其他方式贊助本學會者,或考慮進行方案規畫者,歡迎隨時與本會洽詢。本會將提出合乎個別需求的服務建議。

可事先預約的20分鐘個別會談時段

贊助商與參展者可以事先預約在主要研討會的分科會會議中排定的20分鐘個別會談時段,與希望的對象見面。會期中,Global Engage團隊會常駐會場,協助會談按時進行。

年會前後的研討會

可在年會前後以對特定主題感到興趣者為對象,舉辦為期半天或全天的工作坊活動。Global Engage將協助宣傳以確保工作坊達到足夠的出席人數。

年會開幕前的行銷與宣傳

利用Global Engage的資料庫展開行銷活動,透過海報張貼、休息與午餐會、酒會、贊助海報發表等提高品牌知名度。另備有追加項目可將貴公司的logo印製在發放給與會者的名牌吊繩與年會資料包上。

參展

會議期間設有專用的展示區域,可向所有的與會者展示您的技術與產品。展示區域將設於休息及午餐會,以及第一天晚上的歡迎酒會的舉辦場所。

演講

發言的型態

  • 30分鐘演講
  • 在30分鐘專題討論中擔任主持人或討論人員
  • 在年會議程中舉行一小時的研討會
募集贊助商

歡迎來信或來電與日商環球訊息有限公司台灣分公司聯繫。

包括簽證等各種海關所需文件,以及展示用品的通關手續皆由展商企業各自負責。

展示相關的安排(企業介紹、公司商標、提供與會者目錄中的展商資訊登錄、展示空間的裝潢、用品訂購、展示用品的擺設搬運、展示空間的文件申請、保險等)請直接與主辦方連繫。

旅遊相關疑問(住宿、機票)、當地翻譯人員、飛行與意外保險等問題,將有另外的專門業者分別提供服務。

Adoptive Cell Transfer Congress贊助方案詳情歡迎隨時來信或來電詢問

關於出席與各種方案詳情歡迎隨時詢問。將有專員提供進一步資訊。

媒體合作夥伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免費電子郵件通知服務